 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- MOTIF BIO PLC/S (NASDAQ:MTFB) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap
  medical companies, but which is the superior business? We will contrast the two
  businesses based on the strength of their analyst recommendations, profitability,
  risk, institutional ownership, valuation, dividends...


Reviewing MOTIF BIO PLC/S (NASDAQ:MTFB) & Xenetic Biosciences (NASDAQ:XBIO)

---
- Motif Bio PLC (MTFB:LSE) shares passed above its fifty day moving average during
  trading on Friday . The stock has a fifty day moving average of $0.58 and traded
  as high as $0.73. Motif Bio shares last traded at $0.52, with a volume of 20,767,460
  shares traded. The company has a market cap of $2.80...


Motif Bio (MTFB:LSE) Share Price Passes Above 50-Day Moving Average of $0.58

---
- Motif Bio PLC (MTFB:LSE) shares passed below its fifty day moving average during
  trading on Thursday . The stock has a fifty day moving average of $0.62 and traded
  as low as $0.42. Motif Bio shares last traded at $0.49, with a volume of 6,063,229
  shares. The firm has a market capitalization of $3.37...


Motif Bio (MTFB:LSE) Shares Pass Below Fifty Day Moving Average of $0.62

---
- MOTIF BIO PLC/S (NASDAQ:MTFB) was upgraded by Zacks Investment Research from a hold
  rating to a buy rating in a research report issued to clients and investors on Saturday,
  Zacks.com reports. According to Zacks, Motif Bio plc is a biopharmaceutical company.
  It ...


MOTIF BIO PLC/S (NASDAQ:MTFB) Upgraded to "Buy" at Zacks Investment Research

---
- MOTIF BIO PLC/S (NASDAQ:MTFB) was downgraded by Zacks Investment Research from a
  buy rating to a hold rating in a research report issued on Saturday, Zacks.com reports.
  According to Zacks, Motif Bio plc is a biopharmaceutical company. It engaged in
  the research and development of antibiotics for ...


MOTIF BIO PLC/S (NASDAQ:MTFB) Rating Lowered to Hold at Zacks Investment Research

---
- MOTIF BIO PLC/S (NASDAQ:MTFB) was downgraded by Zacks Investment Research from a
  buy rating to a hold rating in a research report issued on Saturday, Zacks.com reports.
  According to Zacks, Motif Bio plc is a biopharmaceutical company. It engaged in
  the research and...


MOTIF BIO PLC/S (NASDAQ:MTFB) Cut to Hold at Zacks Investment Research

---
- MOTIF BIO PLC/S (NASDAQ:MTFB) was downgraded by Zacks Investment Research from a
  buy rating to a hold rating in a research report issued on Thursday, Zacks.com reports.
  According to Zacks, Motif Bio plc is a biopharmaceutical company. It engaged in
  the research and...


Zacks Investment Research Downgrades MOTIF BIO PLC/S (NASDAQ:MTFB) to Hold

Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.

Market Cap	$0.00
Volume (M)	867,698.00
52-Wk High	$0.00
52-Wk Low	$0.00

MTFB Motif Bio

About

Feed

News

Fundamentals